Benefits of bundled payments turn on whether they are voluntary or mandatory: GAO

FierceHealthcare | January 24, 2019

Benefits of bundled payments turn on whether they are voluntary or mandatory: GAO
CMS suspects Medicare could save money by adopting episode-based payment models. But according to a new report by the the Government Accountability Office, the outcome is highly dependent on the specific structure of those models. In particular, the results can change massively depending on whether the models were voluntary. GAO found (PDF) that mandatory bundles would give the Centers for Medicare & Medicaid Services more consistent results, because practices tend to only participate in the voluntary models when they know they can come out ahead. As a result, voluntary models tend to advantage physicians more than Medicare. "In general, stakeholders reported that voluntary models largely benefit providers. For example, these models tend to have more generous terms and providers can choose to participate in only those models where they are likely to be successful," GAO said. "On the other hand, mandatory models are more likely to give CMS generalizable evaluation results."

Spotlight

Carla Smith, Executive Vice President at HIMSS, highlights the major themes at the upcoming HIMSS Annual Conference and Exhibition in Las Vegas, including the the value of health IT and cybersecurity.


Other News
HEALTH TECHNOLOGY

L2Mtech GmbH Receives CE Mark Approval on 6(SIX) products for Cardiovascular and Endovascular Applications

L2Mtech | February 17, 2021

CE Mark Approval for LimusTrack™, Sirolimus Eluting Coronary Stent System for Cardiovascular Applications. CE Mark Approval for LomiFlow™, Paclitaxel Drug Eluting Balloon for Cardiovascular Applications CE Mark Approval for PearlFlow™, Paclitaxel Drug Elutin Balloon for Endovascular Applications CE Mark Approval for PearlFlow NS™, Self Expandable Nitinol Stent System for Endovascular Applications CE Mark Approval for FlexiTrack 018™, Peripheral Balloon Catheter for Endovascular Applications CE Mark Approval for FlexiTrack 035™, Peripheral Balloon Catheter for Endovascular Applications Bonn, Germany – L2Mtech GmbH has announced the award of its first CE Mark approval on Six (6) products: LimusTrack™ : Sirolimus Coated Cobalt Chromium Stent with biodegradable polymer for the treatment of coronary artery disease, de novo lesions, restenosis lesions. LomiFlow™ : Paclitaxel Coated balloon catheter for the treatment of coronary artery disease, small vessels, dilatation of de novo lesions, in-stent restenosis (ISR) cases. PearlFlow™ : Paclitaxel Coated balloon catheter for the treatment of peripheral arterial disease, PTA, dilatation of stenotic segments or lesions in peripheral arteries. PearlFlow NS™ : Self-Expanding Nitinol Stent System for the treatment of peripheral arterial disease, de novo lesions, lesions in femoropopliteal arteries. FlexiTrack 018™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in femoral, popliteal, tibial arteries. FlexiTrack 035™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in the SFA, femoral arteries. L2Mtech GmbH Founder and CEO Lalit Mamtani said ‘‘We are very excited to have been awarded our first CE Mark on six products, CE Mark approval represents a key milestone for L2Mtech GmbH and is a testament to the efficacy and safety of our innovative technology products for Cardiovascular and Endovascular applications.“ We now prepare to commercially launch the products in all markets where the CE Mark is recognized. With introduction of our innovative technology products in markets, we will be able to expand treatment options for the benefit of many millions of patients with coronary and peripheral artery disease around the world. About L2Mtech Founded in 2017, L2Mtech GmbH is a privately-owned multinational medical device company headquartered at Bonn, Germany. L2Mtech specializes in design, development, manufacture and commercialization of medical devices that are used by healthcare establishments globally. L2MTech will provide interventional physicians with innovative vascular devices including Drug Eluting Balloon manufactured in Europe.Our Core mission is to build a product portfolio focused on minimally invasive treatment for patients with cardiovascular,endovascular and vascular artery disease. For further information, please visit : L2MTech.de Media Contact: L2Mtech GmbH admin@L2Mtech.de +49 228 94730761

Read More

DIGITAL HEALTHCARE

Hero and AdhereHealth Establish Strategic Partnership to Improve Medication Adherence Among Vulnerable Patients

AdhereHealth | December 18, 2021

AdhereHealth, a healthcare technology leader in medication adherence insights and health outcomes, has entered into a strategic partnership with Hero, the market leader in digital in-home care. This new agreement enables AdhereHealth to deploy Hero's digital in-home care platform to help high-risk, high-cost, chronically ill patients adhere to complex medication regimens. Hero's platform includes a connected smart pill dispenser, which automatically sorts and dispenses medications according to a patient's unique medication schedule. Hero's connected app then tracks what a patient took and when, and sends real-time alerts to the patient's care team if a dose is missed or a medication is ready for refill. Hero continually monitors the patient's medication inventory and facilitates real-time medication reconciliation and synchronization. "Combining Hero's industry-leading medication management platform with AdhereHealth's advanced technologies and its nationwide AdhereRx digital pharmacy creates the first complete lifecycle medication management service," said Kal Vepuri, founder and CEO of Hero. "Our partnership will also simultaneously improve patient safety by focusing on medication management, further support caregivers and help people take more control of their health," added Mr. Vepuri. AdhereHealth's digital pharmacy, AdhereRx, leverages data analytics to identify and prioritize vulnerable populations most at risk for nonadherence or drug safety problems. Trained pharmacists then connect via phone with patients to conduct comprehensive medication reviews and address social determinants of health (SDOH) that might get in the way of medication adherence. "Hero's patient-centric technology will enable care managers, providers and health plans to remotely monitor medication intake, providing real-time visibility into how patients are adhering to medication regimens at home. Combined with our medication synchronization technologies and our nationwide AdhereRx digital pharmacy solution, we can drive better patient experience and improve value-based outcomes for vulnerable populations." Jason Z. Rose, CEO of AdhereHealth Poor medication adherence is a leading cause of re-hospitalizations and ER visits, especially among the elderly and those with chronic conditions. The financial impact is significant: medication nonadherence accounts for 16% of U.S. healthcare spending annually, accounting for more than half a trillion dollars. About Hero Hero is a leading digital in-home care platform delivering the first end-to-end medication management service for patients and caregivers. Hero's solution includes its award-winning smart pill dispenser, medication management app, automatic refills with free delivery and 24/7 live support. Since launching in 2018, Hero has dispensed more than 70 million medications. Hero is used as a care management solution by individuals, caregivers and medical providers. About AdhereHealth™ AdhereHealth delivers purpose-built, innovative technology solutions to improve quality of care, medication adherence, and cost outcomes – all with an emphasis on overcoming social determinants of health (SDOH) and improving patient experience. AdhereRx, an AdhereHealth digital pharmacy, provides high-risk, underserved patients with personalized pharmacy services that drive medication compliance and reduce unnecessary utilization costs. This unique combination of predictive analytics, intelligent clinical workflow software and proactive telepharmacy outreach performed by a nationwide team of licensed clinicians addresses an estimated half a trillion dollars of unnecessary annual medical costs attributed to medication adherence issues. Today, the Adhere™ Platform touches nearly 30 million patients across dozens of health plans, self-insured employers and other risk-bearing entities.

Read More

FUTURE OF HEALTHCARE

Ensemble Health Partners, in Partnership with Caduceus Capital Partners, Leads Series A Round for Janus Health

Ensemble Health Partners | December 15, 2021

Ensemble Health Partners, in partnership with Caduceus Capital Partners, led the $8 million Series A capital raise for Janus Health, a revenue cycle automation and decision support platform. Billions of dollars are left uncollected annually by healthcare providers due to poor methods and inconsistent human decision making in the revenue cycle process. Janus Health studies end-user behavior within the revenue cycle and uses advanced AI to determine the optimal path for each workflow. Janus then automates processes and end-to-end workflows using its scalable platform and delivers real-time predictive recommendations to guide human worker performance. “I invest in people first. I’ve known Brendan for a long time, and he has assembled an incredible team who are experts in the field. We see a lot of technology fads in healthcare, but I am always most concerned with delivering value and creating a meaningful impact for our clients and associates. As someone deeply entrenched in the revenue cycle world, I see tremendous potential for Janus to deliver on both fronts.” Judson Ivy, Founder, President and CEO, Ensemble Health Partners “Several factors, including labor shortages, shrinking reimbursements and more stable IT environments, are creating a ripe opportunity to transform the revenue cycle with artificial intelligence and automation,” said Brendan Downing, co-founder and CEO of Janus Health. “Janus Health offers a timely service that can have a significant impact for health systems struggling with these rising costs-to-collect and reimbursement challenges.” Health systems continue to struggle with a workforce shortage and lack of resources. A recent McKinsey & Company study showed that $180 billion could be saved in healthcare administration and finance costs with automated technology. Many health systems do not currently have revenue cycle automation, but plan to implement this technology in the next year. With Janus Health, managers and executives receive actionable insights into people, productivity and practices, allowing them to optimally allocate and manage resources. “The revenue cycle in healthcare is notoriously challenging. Billing and collections are especially complicated when you consider the various payors and parties involved in a transaction,” said Dave Vreeland, senior managing partner at Caduceus Capital Partners. “This area is one of the most labor-intensive in healthcare, and there is a huge opportunity for Janus to make a difference in the industry.” Jim Gaffney, EVP, strategy and corporate development at Ensemble Health Partners and Sue Tyler, venture partner at Caduceus Capital Partners will serve on the Janus Health board of directors. About Ensemble Health Partners Ensemble Health Partners is a leading provider of technology-enabled revenue cycle management solutions for health systems, including hospitals and affiliated physician groups. The company offers end-to-end revenue cycle solutions as well as a comprehensive suite of point solutions to clients across the country. About Caduceus Capital Partners, LLC Caduceus Capital Partners is a venture capital and private equity company focused on early-stage digital health investments. The Caduceus Capital Partners investment model actively supports portfolio companies from the first check to the exit phase with operational expertise and network access to potential customers and partners. About Janus Health Technologies Janus Health is leapfrogging the automation solutions of today by developing the only end-to-end process improvement platform that studies a revenue cycle operation to determine the optimal path of each workflow and rapidly builds intelligent automation and decision support with a single-click.

Read More

DIGITAL HEALTHCARE

AMIH Announces Expansion of EPIQ MD’s Telehealth Platform and Services

Epiq MD | January 21, 2022

American International Holdings Corp., adiversified holding company that develops, acquires and operates technology-based health and wellness companies, today announced that its subsidiaryEPIQ MD, Inc.,has expanded the availability of its telehealth service offerings to thirteen (13) states across the United States. EPIQ MD, Inc., the convergence of primary care, mental health, preventative, and wellness programs through an online healthcare platform, announced its original launch and arrival in four statesback in September of 2021. Now with the introduction of their platform throughout the Southern U. S. border, EPIQ MD is directly on pace to achieve its goal of covering all 50 U. S. states by the year-end 2022 “This expansion of EPIQ MDs telehealth services and offerings across the Southern border of the United States further cements the sentiment that EPIQ MD has held since its official launch in September 2021”, comments Jacob Cohen, President and CEO of American International Holdings Corp. "Our vision is to be an essential service for millions of working families and individuals who currently don’t have any other viable options. Having access to a doctor or mental health professional 24/7/365 represents a crucial advancement in overall quality of life and we simply believe that the more eyes that are opened to EPIQ MD, the more we will be able to grow and expand.” EPIQ MD Director, Michael Ladner EPIQ MD is not simply bringing their expansive array of healthcare services to additional states, but are excited about their most recent introduction of Epiq PAWsand Epiq LUX. Epiq PAWs being EPIQ MD’s virtual care add-on tailored towards furry family members (a/k/a pets), and Epiq LUX being a wide-ranging discount program offering savings on a variety of ancillary medical services, including but not limited to, Laboratory Services, Dental, Vision, Chiropractic, Imaging and Diabetes/Home Medical Supplies. The Company believes that this current footprint represents a great mix of both urban and rural geographic locations, filled with demographics ripe for our primary care and mental health services. Seven of the states listed herein as our coverage area are also within the “top 10 states with the highest percentage of uninsured Americans”, according to the U.S. Central Bureau. While EPIQ MD envisions its platform spreading steadily throughout the United States as the year 2022 progresses, our strategy is to target the areas wherein we can make the biggest difference via our service offering. About EPIQ MD, Inc. EPIQ MD believes that everyone deserves to live an epic life. It is the convergence of primary medical and mental health care, preventative care and wellness programs - on one digital platform, in a single offering. Conceived as a digital telemedicine-based business from the start, its core mission is to bring these services and knowledge to the 80 million Americans who are uninsured or underinsured. Its telemedicine platform provides services such as primary care, medical advisory, ask a medical expert, mental health services, discounted diagnostic lab services, prescription discount program, nutritional counseling and much more. Today Epiq MD is active and operational in Alaska, Georgia, Illinois, Texas, Arizona, New Mexico, Colorado, Louisiana, Mississippi, Alabama, Florida, Nevada and Utah. About American International Holdings Corp. American International Holdings Corp. is an investor, developer and asset manager of diversified, synergistic health and wellness businesses. Today, the AMIH portfolio encompasses telemedicine and other virtual health platforms, affordable subscriber-based primary care and concierge medicine plans, preventative care solutions and wellness related assets such as mental & behavioral health services, as well as its own proprietary life coaching platform. AMIH markets its various services through direct-to-consumer and business-to-business distribution channels. AMIH’s focus is on bringing to market technologies and solutions that advance the quality of life for the global community.

Read More

Spotlight

Carla Smith, Executive Vice President at HIMSS, highlights the major themes at the upcoming HIMSS Annual Conference and Exhibition in Las Vegas, including the the value of health IT and cybersecurity.

Resources